Protein phosphatase-2A activation is a critical step for enzastaurin activity in chronic lymphoid leukemia cells
- 6 December 2011
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (5) , 966-972
Abstract
Targeting B-cell receptor (BCR) downstream pathways may be of therapeutic importance in eradicating chronic lymphocytic leukemia (CLL) cells. Since protein kinase C-βII (PKC-βII) is a key element of BCR signaling, we evaluated the impact of enzastaurin on cell survival. Enzastaurin classically activates glycogen synthase kinase-3β through inhibition of PKC-β, Akt and target of rapamycin pathways in cancer cell lines. Here, we show that in primary CLL cells, enzastaurin activates protein phosphatase-2A (PP-2A) to mediate dephosphorylating events in responding patients. In patients’ cells, both PP-2A activation and Bcl-2 dephosphorylation are statistically linked to enzastaurin-induced CLL death. Protein phosphatase-2A inhibition, through pharmacological agents or siRNA, significantly hampers cell death induced by the drug. Despite limited activity in in vitro culture, enzastaurin is able to sensitize CLL cells to fludarabine, even in patients refractory to either agent used alone. These results argue for the use of enzastaurin in combination therapy in patients with CLL.Keywords
This publication has 30 references indexed in Scilit:
- Molecular and cellular mechanisms of CLL: novel therapeutic approachesNature Reviews Clinical Oncology, 2009
- Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cellsLeukemia, 2008
- ITAM-mediated tonic signalling through pre-BCR and BCR complexesNature Reviews Immunology, 2006
- Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLLLeukemia, 2006
- Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosisJournal of Clinical Investigation, 2005
- ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2004
- B Cell Chronic Lymphocytic Leukemia: Lessons Learned from Studies of the B Cell Antigen ReceptorAnnual Review of Immunology, 2003
- B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytesBlood, 2002
- Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic LeukemiaJournal of Experimental Medicine, 2001
- Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic LeukemiaBlood, 1999